S&P 500 Index Outlook: Top Three Catalysts for US Stocks This Week
This S&P 500 Index outlook explores the top catalysts for US stocks this week, including US consumer and producer inflation.
Stocks · News reference
This Adobe Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Top analysts upgraded Palantir, Silicom, Adobe, and Chevron. See what other analysts think about these stocks. Photo via Shutterstock.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Consumer Tech (Aug 31-Sep 4): NVIDIA Buys World's Largest Open AI Developer, Trump Claims Total Control On Hormuz & More
President Donald Trump recently claimed the U.S. has “total control” over the Strait. NVIDIA acquire Hugging Face for $12.93 billion.
Earnings Volatility Watch: Oracle And Adobe Report, But the Wild Swings Belong to Smaller Names
Oracle and Adobe headline the week, both down about 20% in 2026, yet the biggest implied earnings moves belong to InnovAge, SailPoint and eight others.
Shares of software companies are trading lower after August's hotter-than-expected payrolls report increased expectations that the Federal Reserve could raise interest rates at its next meeting. A stronger U.S. dollar and higher rate expectations are weighing on growth stocks by reducing investor appetite for higher-risk assets.
mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More
The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.
Got $10,000 to Invest in This High-Yield, Midstream Stock? Here's What It Could Be Worth in 10 Years.
Hess Midstream LP (HESM) is highlighted as an attractive midstream energy investment opportunity, offering a 7.7% dividend yield with quarterly increases over nine years. The company operates oil, gas, and produced water handling assets in North Dakota's Bakken and Three Forks Shale plays. Its corporate structure was restructured in 2019 to simplify tax treatment for investors.